BCPWM
GILD icon

Bradley & Co Private Wealth Management’s Gilead Sciences GILD Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50
Closed -$4.29K – 170
2022
Q4 		$4.29K Hold
50
– – 0.01% 140
2022
Q3 		$3K Hold
50
– – ﹤0.01% 160
2022
Q2 		$3K Buy
+50
New +$3.1K ﹤0.01% 164

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bradley & Co Private Wealth Management's GILD Position: Q1 2023 in Review

Bradley & Co Private Wealth Management sold out of Gilead Sciences (GILD) in Q1 2023, closing a stake of 50 shares — an estimated $4.29K sold.

Bradley & Co Private Wealth Management first reported a position in GILD in Q2 2022 and held it in 3 quarters. The position peaked at $4.29K in Q4 2022. 1,735 funds tracked by Wall St. Rank hold GILD as of Q1 2023.

  • Bradley & Co Private Wealth Management reported no remaining Gilead Sciences position as of Q1 2023 after selling out during the quarter.
  • Bradley & Co Private Wealth Management sold 50 Gilead Sciences shares in Q1 2023, an estimated $4.29K.
  • Bradley & Co Private Wealth Management first reported a position in Gilead Sciences in Q2 2022 and held it in 3 quarters.
  • Bradley & Co Private Wealth Management's Gilead Sciences position peaked at $4.29K in Q4 2022.
  • 1,735 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2023.

Based on Bradley & Co Private Wealth Management's 13F filing for Q1 2023, filed 9 May 2023.